To study the effect of herbal formulation in the management of newly diagnosed mild COVID-19 patients, to reduce the risk of hospitalization or death.
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2022/07/044204
- Lead Sponsor
- All India Institute of Ayurveda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Subject aged 18 to 70 years (both inclusive) of both gender
Subject with SARS-CoV-2 infection confirmed through reverse transcription followed by polymerase chain reaction (RT- PCR)
RT PCR negative COVID 19 suspected symptomatic subject defined as having strong suspicion of atleast 3 or more symptoms as per WHO or ICMR compatible with covid 19 and or having exposure to Covid 19 cases
Subject with mild manifestations of COVID-19 (ICMR guidelines, 2022)
Subject with initial onset of signs/symptoms attributable to COVID-19 for <=5 days prior to the day of randomization
Subject with ability to swallow and retain oral medication
Subject with willingness and ability to comply with trial and follow-up procedures.
Subject with ability to understand the nature of this trial and give written informed consent
Subject with RT-PCR positive COVID-19 with no symptoms
Subject who is currently hospitalized or is expected to need hospitalization for COVID-19 within 48 hours of randomization.
Subject with moderate, severe and critical COVID-19 (ICMR guidelines, 2022)
Subject in which the present episode of infection is a recurrence or reinfection of COVID-19 (within 90 days)
Subject with underlying non-Communicable diseases like cardiovascular disease, hypertension, and CAD, DM (Diabetes Mellitus) and other immunocompromised states, active tuberculosis, chronic lung/kidney/liver disease, cerebrovascular diseases and obesity
Subject with aspartate aminotransferase (AST)/alanine transaminase (ALT) more than 3 times the upper limit of normal reference range
Subject who is pregnant, lactating or planning pregnancy during the study period
Subject on steroid or other immunosuppressive medication
Subject with a history of receiving any allopathic or alternative (herbal) medication, any antiviral drugs with reported activity against COVID-19 (ivermectin, favipiravir, hydroxychloroquine, lopinavir, and remdesivir) or warfarin therapy for the present COVID-19 episode within 7 days before enrolment
Subject with unstable or life-threatening systemic diseases like immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) with cirrhosis, end-stage liver disease, carcinoma, respiratory failure and end stage renal disease
Subject with a platelet count <100,000/μL or who have received a platelet transfusion in the 5 days prior to randomization
Subject having hypersensitivity or other contraindication to any of the components of the study interventions as determined by the principal investigator
Subject with conditions that could limit gastrointestinal absorption of tablet contents
Subject who is already participating in another trial or have received an experimental drug or have used an experimental medical device within 30 days prior to the planned start of procedure
Subject unlikely to comply with the procedure or complete the scheduled follow up visit, in the opinion of principal investigator
Employee of the principal investigator or study center with direct involvement in the proposed study or other studies under the direction of that principal investigator or study center
Other indication-based exclusion, in opinion of principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of participants with mild COVID-19 (as per ICMR guidelines, 2022) who are hospitalized and/or die due to COVID-19 through day 30Timepoint: Day 1, Day 3, Day 5, Day 11-12,Day 15, Day 30/early termination visits
- Secondary Outcome Measures
Name Time Method